In-life toxicology studies are expensive in terms of man-power, amount of materials and time required to perform a complete evaluation. Lower cost, faster and higher throughput screens that can predict those compounds that are not worth the cost and expense of conducting pilot toxicity studies will increase the success rate of compounds entering pilot studies, provide significant savings to companies performing pharmaceutical R&D, and reduce unproductive laboratory animal usage. This session will focus on the promise and implementation of new approaches to preclinical safety liability assessment and the challenges of translating preclinical results to human risk assessment in this context.

• Discuss and define goals and expectations for early preclinical safety liability testing
• Report on progress and challenges with new preclinical safety asessment technologies
• Discuss and define critical parameters for adoption of new preclinical safety assessment technologies